Redcare Pharmacy NV banner

Redcare Pharmacy NV
F:RDC

Watchlist Manager
Redcare Pharmacy NV Logo
Redcare Pharmacy NV
F:RDC
Watchlist
Price: 45.32 EUR -2.12% Market Closed
Market Cap: €824.8m

Redcare Pharmacy NV
Investor Relations

Redcare Pharmacy is an online pharmacy group that sells prescription medicines, over-the-counter drugs, and everyday health and wellness products. Customers order through its websites and apps, and the company fulfills those orders from regulated pharmacy operations. In some markets, it also helps patients use digital prescriptions and related pharmacy services. Its main customers are consumers who want medicines and health products delivered to their home, along with people who prefer to manage repeat prescriptions online. Redcare makes money mainly by selling products directly to shoppers and by handling prescription orders for reimbursed medicines where payment flows through insurers or national health systems. Because it sits at the meeting point of retail pharmacy, logistics, and digital healthcare, the business depends on efficient fulfillment, compliance with pharmacy rules, and trust from both patients and healthcare partners. What makes Redcare different is that it is not a traditional corner pharmacy chain. It combines a pharmacy license, an online storefront, and a delivery network, which lets it serve customers without requiring them to visit a store. That model gives it a clear role in the pharmacy value chain: it brings medicines and health products to consumers through digital ordering and mail delivery rather than through a physical counter.

Show more
Loading...
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q3 2025
Call Date
Oct 29, 2025
AI Summary
Q3 2025

Strong Sales Growth: Group sales rose 27% year-over-year for the first 9 months, driven by both Rx and non-Rx segments, with particularly fast growth in Germany.

Rx Expansion: German Rx sales surged 122% YoY, and the company has increased market share in this segment to 0.94%, with e-script market share at 1.19%.

Margin Improvement: Adjusted EBITDA margin reached 2.1% for the year-to-date and 2.4% in Q3, both within full-year guidance.

Cash Flow & Funding: Operating cash flow remains strong and positive, even with significant Rx marketing spend, and the company is fully funded for current and upcoming investments.

Guidance Confirmed: Management reiterated guidance: sales growth of over 25% for the full year, non-Rx growth above 18%, and an adjusted EBITDA margin between 2% and 2.5%.

Operational Investments: Major logistics investments are on track and fully funded, with the new Pilsen site operational and automation in Sevenum progressing.

Competition & Strategy: Management remains confident in its online pharmacy positioning despite reports of new entrants in the German OTC market.

Key Financials
Sales (Q3)
EUR 790 million
Sales (9 months YTD)
EUR 2.15 billion
Adjusted EBITDA (Q3)
EUR 17 million
Adjusted EBITDA (9 months YTD)
EUR 44 million
Adjusted EBITDA margin (Q3)
2.4%
Adjusted EBITDA margin (9 months YTD)
2.1%
Cash (end of September)
EUR 266 million
German Rx Market Share (Q3 annualized)
0.94%
German Rx Sales (Q3 annualized)
EUR 520 million
Non-Rx Growth
up 18% YoY
Repeat Order Rate
90%
Net Promoter Score (NPS)
72
Operating Cash Flow (rolling, excl. Rx Germany)
EUR 100 million
Operating Cash Flow (rolling, total company)
EUR 32.8 million
Other Earnings Calls

Management

Mr. Olaf Heinrich
CEO & Member of the Managing Board
No Bio Available
Mr. Marc Fischer
Co-Founder & Advisor
No Bio Available
Ms. Theresa Holler
COO & Member of the Managing Board
No Bio Available
Mr. Dirk Bruse
Chief Commercial Officer & Member of Management Board
No Bio Available
Mr. Lode Fastré
Chief Information Officer & Member of Management Board
No Bio Available
Mr. Patrick Schneider
Chief Sales Officer
No Bio Available
Ms. Beate Krosch
Director of Human Resources
No Bio Available
Mr. Nana Lohmanns
Chief E-Health Officer
No Bio Available
Mr. Jens Wolfgarten
Chief Product Officer - Retail
No Bio Available

Contacts

Address
LIMBURG
Sevenum
Erik de Rodeweg 11/13
Contacts
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett